According to a multi-center clinical trial led by researchers at the Stanford University School of Medicine, a new type of immunotherapy seems to be safe for patients with blood cancer called non-Hodgkin’s lymphoma.
The therapy combines experimental antibodies developed by researchers at Stanford University and commercially available anti-cancer antibodies to rituximab. It referred Hu5F9-G4 experimental protein antibody blockade of CD47 , of CD47 suppressed immune attack against cancer cells. The combination of two antibodies is used to treat people with two types of ikke-Hodgkins lymfom: diffuse large B- cell lymphoma and follicular lymphoma.
I 2010 viste forskere ledet av Irving Weissman, MD, direktør for Stanford Stem Cell Biology and Regenerative Medicine Institute, at nesten alle kreftceller er dekket med et protein som heter CD47, som kan spille et "ikke spise meg" -signal til makrofager.
Weissman and colleagues later developed an antibody called Hu5F9-G4 that blocks the CD47 protein and encourages macrophages to engulf cancer cells. Rituximab is an antibody that has been shown to amplify the positive ” eat me ” signal. The combination of rituximab and Hu5F-G4 has previously been shown to be effective against human cancer in animal models, but this is the first published result of clinical trials of the therapy in humans.
Av de 22 pasientene som deltok i studien, hadde 11 pasienter signifikant redusert klinisk kreft, og 8 pasienter hadde eliminert alle tegn på kreft. De tre andre pasientene i studien svarte ikke på behandlingen og døde på grunn av sykdomsprogresjon. Forskerne observerte at deltakerne bare hadde mindre bivirkninger.
Dr. Saul A. Rosenberg , a lymphoma professor , said that such a potential new immunterapi is very exciting. This is the first time that an antibody that can activate macrophages to fight cancer is used, and it seems to be safe for use in humans.
https://medicalxpress.com/news/2018-10-anti-cd47-cancer-therapy-safe-small.html
